We previously identified a novel p53 target gene, RTVP-1, that possesses unique cytotoxic and immunostimulatory activities which make it potentially useful for cancer gene therapy. To test the therapeutic potential of RTVP-1 in a gene-modified tumor cell-based vaccine model, we used an adenoviral vector capable of efficient transduction and expression of RTVP-1 (AdRTVP-1), together with a highly metastatic mouse prostate cancer cell line (178-2 BMA). A vaccine was prepared with 178-2 BMA cells transduced with AdRTVP-1 or a control adenoviral vector expressing b-galactosidase (Adbgal). After irradiation of the cells, syngeneic 129/Sv mice were vaccinated three times at weekly intervals. After 3 weeks, they were challenged with orthotopic 178-2 BMA cells. After 21 days, fewer than 60% of the RTVP-1-cell-vaccinated mice developed tumors compared to 100% of the control mice. The RTVP-1-cell vaccine significantly reduced primary tumor wet weight compared with control Adbgal-cell vaccine (Po0.0001 at 7 and 14 days). Experimental metastasis to lung was also significantly reduced (P ¼ 0.0377), and survival significantly increased (P ¼ 0.0002). In addition, significantly increased NK and CTL activities were demonstrated in the AdRTVP-1-cell-vaccinated mice. These findings indicate that RTVP-1 gene-modified cell-based vaccines may be useful in the prevention of recurrent prostate cancer.
Introduction
Prostate cancer will be diagnosed in over 230 000 American men in 2005, and may possibly result in 30 350 deaths. 1 At least 50 000 men every year show increases in their serum PSA level 2 after presumed definitive localized therapy, that is, radical prostatectomy and irradiation. This large group of men face considerable uncertainty regarding the progression of their disease and have limited treatment options. Vaccine or immunotherapy is likely to be safe and potentially effective for these men. 3 A variety of putative defined tumor antigens such as PSA, PSMA, PAP, MUC-1, NY-ESO have been tested or proposed for use as prostate cancer vaccines. 3, 4 However, the antigenic properties of these proteins are not optimal, 5, 6 and multiple clinical trials that have tested these proteins as full-length proteins or peptide derivatives as primary vaccines have, in general, failed to show significant clinical responses. 3, 7, 8 Tumor RNA 9 or whole cell vaccines, however, offer the advantage of multiple tumor antigen epitopes, and may ultimately prove to have significant advantages. Specific vaccine approaches that involve gene-modified and irradiated whole tumor have also been considered and have advanced to clinical trials for many malignancies. 5 The concept of antitumor vaccination for prostate cancer was established in preclinical studies with irradiated GM-CSF-secreting Dunning rat prostate carcinoma cells as a vaccine. 10 This led to a clinical trial in which patients with prostate cancer were treated with autologous GM-CSF-secreting, irradiated autologous tumor cell vaccines prepared by ex vivo retroviral transduction of surgically harvested cells. 11, 12 In this study, we evaluate a whole cell vaccine approach that may have enhanced efficacy through the use of an immune enhancing gene called RTVP-1 that we identified as important in prostate cancer.
We identified the mouse RTVP-1 (related to testesspecific, vespid and pathogenesis proteins) mRNA as being upregulated by p53 in mouse prostate cancer cells. 13 The human RTVP-1 cDNA was originally cloned from human glioma tissue, 14, 15 and subsequently reported to be expressed in differentiated macrophages. 16 In our initial report, we showed that RTVP-1 is regulated by p53 through specific p53-binding sites, and that overexpression of RTVP-1 in vitro leads to apoptosis in multiple mouse and human cancer cell lines and in endothelial cells. 13 Recently, we have extended these studies to show that the human RTVP-1 gene is also regulated by p53, functions as a tumor suppressor and is inactivated by gene methylation in prostate cancer. 17 In a preclinical gene therapy model, we demonstrated that adenoviral vectormediated RTVP-1 expression can suppress growth and metastasis of prostate cancer in vivo, 18 and that these effects are mediated by proapoptotic, antiangiogenic and immunostimulatory activities. In the present study, we tested the ability of RTVP-1 to enhance the therapeutic potential of whole tumor cell vaccination in a metastatic prostate cancer model designed to mimic the effects of recurrent prostate cancer in humans. Specifically, the highly metastatic mouse prostate cancer cell line 178-2 BMA was transduced with an adenoviral vector that expresses RTVP-1 (AdRTVP-1), then irradiated and used as a vaccine. Tumor challenge consisted of orthotopic 178-2 BMA cells. We show that the RTVP-1-transduced 178-2BMA cell vaccine has significant antitumor activities in this prevention model. The use of adenoviral vectormediated, gene-modified tumor cell therapy could potentially address the need for neoadjuvant and adjuvant approaches to suppress recurrence following standard therapies for presumed localized prostate cancer.
Materials and methods

Cells and adenoviral vectors
The mouse prostate cancer cell line 178-2 BMA was derived from a bone metastasis derived from a primary carcinoma arising within Zipras/myc-infected urogenital sinus tissue obtained from p53 heterozygous 129/Sv mice using the metastatic mouse prostate reconstitution (MPR) model system as previously described. 19 Cells were grown as previously described. 18, [20] [21] [22] The replication-defective adenoviral vector expressing RTVP-1 (AdRTVP-1) and a control adenoviral vector containing the b-galactosidase gene (Adbgal) were prepared as described, 18 and viral concentration was expressed as plaque-forming units. Western blotting with affinity-purified antibody to RTVP-1 was as described. 13 Cell-based vaccine and orthotopic mouse prostate cancer model 178-2 BMA cells were transduced at a multiplicity of infection (moi) of 100. Cells were infected for 3 h in serum-free medium, then removed, and fresh serum containing medium was added. The next day, the cells were irradiated at 100 Gy and used directly as a vaccine by injecting 1 Â 10 6 cells subcutaneously into syngeneic 129/Sv mice. Mice were vaccinated on days 0, 7 and 14, and then challenged 21 days after the last vaccination with 5 Â 10 3 178-2 BMA cells injected into the prostate in a volume of 10 ml in Hanks' balanced salt solution. To evaluate the effect of vaccination on the development of lung metastases, some mice received a tail vein injection (5 Â 10 3 cells) at the same time as the orthotopic injection. Animals were evaluated on days 3, 7, 14 and 21 after the orthotopic injection for therapeutic effects. Pathological evaluation was performed on all tumor and metastatic tissues as previously described. 18 Immunohistochemical detection of CD4 þ T cells, CD8 þ T cells and F4/80 þ macrophage was as described. 18 Tumor incidence or tumor take was confirmed by the evaluation of hematoxylin and eosin-stained sections. For survival analysis, animals were evaluated at death or euthanized when in distress, as evidenced by lethargy, ruffled fur, or weight loss and survival plotted by Kaplan-Meier actuarial analysis as previously described. 18 Mice were maintained in facilities accredited by the American Association for Accreditation of Laboratory Animal Care, and all experiments were conducted in accordance with the principles and procedures outlined in the National Institutes of Health's Guide for the Care and Use of Laboratory Animals.
In vitro cytolytic assays NK activity was determined by the lysis of 51 Cr-labeled YAC cells with splenocytes derived from tumor-bearing animals essentially as described previously. 18 Cytolytic T lymphocyte activity was determined by the lysis of target 51 Cr-labeled, IFN-g-stimulated 178-2 BMA cells as described. 18, 23 In vitro depletion of CD8 þ and CD4 þ T cells was accomplished by treatment of splenocytes immediately after isolation, with supernatants from the hybridoma HO-2.2 (anti-Lyt 2.2) or GK1.5 (anti-L3T4), followed by complement lysis. 18 Statistical analysis Analysis of variance (ANOVA) was used to make comparisons between the means. Sample size for each experiment was determined by assuming that the difference would be of a similar magnitude to that between control and AdRTVP-1-treated animals in previous studies. 18 Kaplan-Meier survival analysis was evaluated with the log-rank Mantel-Cox test. All analyses were performed with Statview 5.0 (SAS Institute Inc., Cary, NC).
Results
Transduction with AdRTVP-1 induces RTVP-1 expression To test the therapeutic potential of adenoviral vectormediated RTVP-1 gene-modified prostate cancer cellbased vaccine, we designed a model to mimic the effects of recurrent prostate cancer in humans (Figure 1a ). Mice were vaccinated once a week for three times with the prostate cancer cell line 178-2 BMA that had been genemodified and then irradiated. After a three-week interval, the vaccinated mice were challenged with an orthotopic injection of live 178-2 BMA cells. A tail vein injection at the same time as the orthotopic injection served as a direct lung metastasis challenge.
AdRTVP-1 transduction of 178-2 BMA cells led to a dose-dependent increase in the expression of RTVP-1 protein (Figure 1b) . Based on these results, we chose an moi of 100 for further studies. The expression of RTVP-1 was not induced by Adbgal transduction.
Therapeutic effects of RTVP-1 gene-modified cell-based vaccine To determine possible tumorigenesis prevention activities induced by AdRTVP-1-modified tumor cell vaccine in vivo, 3 weeks after a course of three weekly vaccinations, 178-2 BMA cells (5 Â 10 3 cells) were injected directly into the dorsolateral prostate. At 3, 7, 14 and 21 days after tumor challenge, tumors were recovered from animals and the wet weight of primary tumors was analyzed. As shown in Figure 2a , significant suppression of tumor (prostate) weight was observed in the AdRTVP-1-cellvaccinated group (n ¼ 23) compared with the Adbgal-cellvaccinated group (n ¼ 12) or the HBSS group (n ¼ 9) at day 14 (P ¼ 0.0003, AdRTVP-1-cell vs HBSS; P ¼ 0.0018, AdRTVP-1 cell vs Adbgal cell; P ¼ 0.4326, Adbgal cell vs HBSS). In addition, there were significant differences at day 21 (Po0.0001, AdRTVP-1 cell vs HBSS; Po0.0001, AdRTVP-1 cell vs Adbgal cell; P ¼ 0.1596, Adbgal cell vs HBSS). Importantly, the incidence of tumor formation in AdRTVP-1-cell-vaccinated mice was significantly inhibited at day 14 (26% incidence, Po0.0001, w 2 ), and day 21 (58% incidence, P ¼ 0.0068, w 2 ) compared to 100% incidence in the control HBSS group and Adbgal-cellvaccinated mice at both time points (Table 1) .
To evaluate potential antimetastatic effects of RTVP-1 gene-modified cell-based vaccination, we analyzed the extent of lung metastases in AdRTVP-1-cell-or Adbgalcell-vaccinated animals challenged with 178-2 BMA cells orthotopically and via the tail vein. AdRTVP-1 cell vaccination (n ¼ 8) significantly suppressed experimental 
a Tumor incidence was determined by analysis of the wet weight of the prostate relative to uninjected control prostate wet weight and confirmed by microscopic evaluation. We analyzed systemic immune responses in animals following vaccination by measuring NK and CTL activities. As shown in Figure 3b , significantly increased NK activities were demonstrated in splenocytes isolated from mice vaccinated with AdRTVP-1 cells compared with the Adbgal cell vaccine or HBSS (negative control) 3 days after orthotopic 178-2 BMA tumor challenge (P ¼ 0.0001, E:T ratio of 100:1). Splenocytes from vaccinated mice were also evaluated for their ability to lyse 178-2 BMA cells in vitro 7 days after orthotopic 178-2 BMA challenge (Figure 3c) . A significant increase in CTL activity was observed at an E:T ratio of 100:1 (P ¼ 0.0121, AdRTVP-1 cell vs HBSS; P ¼ 0.0231, AdRTVP-1 cell vs Adbgal cell). Lysis of non-prostatic cells was not observed (data not shown). To verify that CD8 þ T cells were responsible for this activity, we selectively depleted splenocytes of either CD4 þ cells or CD8 þ cells by antibody-mediated complement lysis before performing the CTL assay. As shown in Figure 3d , a significant reduction of lytic activity was obtained with CD8 þ cell-depleted (P ¼ 0.0016), but not CD4 þ cell-depleted effector cells (P ¼ 0.8389).
Discussion
We have previously shown that the overexpression of RTVP-1 in prostate cancer through adenoviral vector transfer induces local tumor cell cytotoxicity that is mediated directly by apoptotic pathways and indirectly by antiangiogenic and local and systemic antitumor immune responses. 18 We undertook these preclinical studies to evaluate the therapeutic potential of RTVP-1 as an immunostimulatory molecule within the context of a whole tumor cell vaccine. The RTVP-1 gene-modified cell-based vaccine led to significantly decreased tumor growth, increased growth suppression, decreased metastasis and prolonged survival compared to a control genemodified cell-based vaccine. All non-vaccinated and Adbgal-cell-vaccinated mice formed tumors and Adbgalcell-vaccinated mice failed to suppress tumor growth or inhibit experimental lung metastasis. Interestingly, we observed a slight survival advantage for Adbgal-cellvaccinated mice compared to HBSS control mice (Figure 2c ), suggesting some level of intrinsic tumor immunogenicity.
Our previous report demonstrated that both CTL and NK cells play important roles in the antitumor effects of in situ AdRTVP-1 gene therapy. The current studies show that RTVP-1 enhanced vaccine efficacy by generating both NK and CTL activities. As we did not positively identify the effector population as being exclusively NK cells in our NK activity assays, it is conceivable that other MHC-unrestricted killing activities are also activated by RTVP-1 enhanced vaccine. We speculate that macrophages or dendritic cells are directly activated by RTVP-1 protein, which is likely secreted by the AdRTVP-1-infected tumor cells used for the vaccine. 13 Antigenpresenting cells may also be activated by the uptake of tumor cell-derived peptides generated by direct RTVP-1-mediated cytotoxicity. 13, 18 As tumor cells were engineered to overexpress RTVP-1, it is also conceivable that this protein could be functioning as a tumor antigen. Because RTVP-1 is induced during the differentiation of specific antigen-presenting cells, 16 we favor the notion that intrinsic immunostimulatory properties of RTVP-1 are more related to the activation of downstream, potentially receptor-mediated, signaling cascades within antigenpresenting cells rather than intrinsic antigenic properties. As we have shown that the expression of RTVP-1 is significantly reduced in advanced cancers, 17 the therapeutic use of RTVP-1 is less appealing as a tumor antigen than as an immunomodulator.
Recent developments in cancer vaccine research are based on advances in the identification and characterization of tumor-associated antigens and better understanding of the regulatory molecules involved in cell-mediated immunity. 24 However, despite their apparent safety and ability to elicit positive surrogate end points such as detectable immune responses, there has been a general absence of clinical regression of tumors clinically. 8 Prostate cancer presents additional problems because of the lack of well-defined tumor-associated antigens. Yet the widespread use of radical prostatectomy as an initial therapy for prostate cancer provides the opportunity to obtain whole tumor cells. Adenoviral-mediated RTVP-1 transduction of whole tumor cells obtained from radical prostatectomy specimens or, possibly, biopsies may þ or CD4 þ splenocytes before CTL assay on day 7 after orthotopic 178-2 BMA cell injection (*Po0.05; **Po0.01; n ¼ 3 per group). Bars ¼ SEM.
RTVP-1 vaccine for prostate cancer
K Naruishi et al generate a tumor cell-based vaccine with enhanced efficacy. Vaccination could be particularly useful in patients who experience biochemical recurrence. Thus, the use of adenoviral vector-mediated RTVP-1 genemodified tumor cell therapy could potentially address the need for neoadjuvant and adjuvant approaches to suppress recurrent prostate cancer following standard therapies for presumed localized disease.
